Is Bioventus Inc. (BVS) a Buy, Sell, or Hold?
Bioventus Inc.
NASDAQ:BVS
$11.56 USD
-$0.51 (-4.23%)
- Volume
- 530.14K
- Average Volume
- 651.7K
- Market Capitalization
- $783.17M
- P/E Ratio
- 27.30
- Dividend Yield
- 0.00%
- Price Target
- $14.00
- Year High
- $12.30
- Year Low
- $5.81
- Day High
- —
- Day Low
- —
- Payout Ratio
- $0.00
- Current Ratio
- $1.69
Industry, Sector & symbol
| Stock Exchange | NASDAQ |
| CEO | Robert Claypoole |
| Industry | Medical - Devices |
| Sector | Healthcare |
| Current Symbol | BVS |
| CUSIP | 09075A108 |
| CIK | 0001665988 |
| Web | http://www.bioventus.com |
| Phone | 919 474 6700 |
| Currency | USD |
| Employees | 930 |
| Country | US |
Liquidity
| Debt-to-Equity Ratio | 1.44 |
| Payout Ratio | 0.00 |
| Current Ratio | 1.69 |
| Quick Ratio | 1.13 |
| Cash Ratio | 0.24 |
Sales & Book Value
| Annual Sales | $568.09M |
| Price / Sales | 1.36 |
| Cash Flow | 1.50 |
| Price / Cash Flow | 7.78 |
| Price / Book | 4.12 |
Price Target and Rating
| Average Stock Price Forecast | $14.00 |
| High Stock Price Forecast | $15.00 |
| Low Stock Price Forecast | $13.00 |
| Forecast Upside/Downside | -17.43% |
| Consensus Rating | Neutral |
| Rating Score(0-5) | 3 |
| Research Coverage | 6 Analysts |
Profitability
| EPS (Most Recent Fiscal Year) | $0.33 |
| Trailing P/E Ratio | 27.30 |
| PEG Ratio | 0.00 |
| P/E Growth | 0.00 |
| Net Income | $22.73M |
| Net Margin | 4.94% |
| Pretax Margin | 5.84% |
| Return on Equity | 16.27% |
| Return on Assets | 4.38% |
Financials Score
| AltmanZ Score | 1.77 |
| Piotroski Score | 8.00 |
| Working Capital | 101.72M |
| Total Assets | 650.54M |
| Ebit | 56.95M |
| Market Cap | 780.52M |
| Total Liabilities | 416.27M |
Poll Results
About Bioventus Inc. (NASDAQ:BVS) Stock
Bioventus Inc., a medical device company, focuses on relieving pain and addressing musculoskeletal therapies in the United States and internationally. The company’s product portfolio includes pain treatments, which comprise various intra-articular and hyaluronic acid injections; peripheral nerve stimulation products, such as Durolane, GELSYN-3, and SUPARTZ for the treatment of knee osteoarthritis; and Stimrouter to treat chronic peripheral pain, and TalisMann provides stimulation to the targeted peripheral nerve, as well as XCELL PRP System, a benchtop device that processes whole blood to produce high-yield PRP with a 10-minute single-spin cycle. It also offers precision bone resection for patients with degenerative spine conditions and spinal deformities, as well as enables precision ultr ... asonic neuro and general surgery to address brain tumors and pathologies of the liver and other organs; and bone graft substitutes, including various products that facilitate optimal bone fusion. In addition, the company provides neXus, an ultrasonic surgical system; BoneScalpel, a surgical solution enabling precise cuts in hard tissue; BoneScalpel Access, for bone removal with visualization; SonaStar system, a precise ablation and removal of soft tissue; SonaStar Elite handpiece and accessories; SonicOne, an ultrasonic cleansing and debridement system; Osteoamp, an allograft-derived bone graft for orthopedic, neurosurgical, and reconstructive bone grafting procedures; Signafuse bone graft; Purebone, a natural osteoconductive scaffold; and Reficio demineralized bone matrix. The company’s restorative therapies include minimally invasive fracture treatments and rehabilitation products. Its products also include Exogen, an ultrasound bone stimulation system. The company sells its products to healthcare institutions, physicians, patients, distributors and dealers. Bioventus Inc. was founded in 2011 and is headquartered in Durham, North Carolina.
Are You Looking for a Top Momentum Pick? Why Bioventus (BVS) is a Great Choice
2026-07-08 13:01:11
Does Bioventus (BVS) have what it takes to be a top stock pick for momentum investors? Let's find out.
Wall Street Analysts Predict a 28.81% Upside in Bioventus (BVS): Here's What You Should Know
2026-07-08 10:55:25
The mean of analysts' price targets for Bioventus (BVS) points to a 28.8% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
Bioventus: I See A Better Business Trading At A Fair Price (Upgrade)
2026-07-07 11:13:29
Bioventus Inc. develops medical devices and biologics for orthopedic recovery and pain relief. I previously rated it a 'Hold' due to debt, competition, weak cash flow, and valuation concerns despite strong Q2 2024 growth. BVS has recently outperformed the S&P 500 and medtech ETFs, with a breakout driven by favorable regulatory developments.
Bioventus (BVS) Soars 12.4%: Is Further Upside Left in the Stock?
2026-07-07 09:21:05
Bioventus (BVS) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.
Did Bioventus Inc. Insiders Breach their Fiduciary Duties to Shareholders?
2026-07-03 12:24:00
Shareholders are encouraged to contact the firm to discuss their rights and options at no cost or obligation. We would handle any matter on a contingent fee basis, whereby you would not be responsible for out-of-pocket payment of our legal fees or expenses.
3 Top Breakout Stocks to Snap Up for Big Upside in July 2026
2026-07-02 16:01:04
FA, BVS and OOMA emerged as July breakout stock picks after meeting momentum and price-based screens designed to spot potential upside.
Should Value Investors Buy Bioventus (BVS) Stock?
2026-06-25 10:41:21
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
Are Investors Undervaluing Bioventus (BVS) Right Now?
2026-06-09 10:41:17
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
Frequently Asked Questions
-
What is the current Bioventus Inc. (BVS) stock price?
-
Bioventus Inc.(NASDAQ:BVS) stock price is $11.56 in the last trading session. During the trading session, BVS stock reached the peak price of $12.3 while $5.81 was the lowest point it dropped to. The percentage change in BVS stock occurred in the recent session was --4.23% while the dollar amount for the price change in BVS stock was -$-0.51.
-
BVS's industry and sector of operation?
-
The NASDAQ listed BVS is part of Medical - Devices industry that operates in the broader Healthcare sector.
-
Who are the executives of BVS?
-
Anthony D'Adamio | Senior Vice President, General Counsel & Corporate Secretary
Mark Singleton | Senior Vice President & Chief Financial Officer
Robert Claypoole | President, Chief Executive Officer & Director
Dave Venner | Senior Vice President & GM of Surgical
Helen Leupold | Senior Vice President & Chief Human Resources Officer -
How many employees does BVS have?
-
Number of BVS employees currently stands at 930. BVS operates from 4721 Emperor Boulevard, Durham, NC 27703, US.
-
Link for BVS official website?
-
Official Website of BVS is: http://www.bioventus.com
-
How do I contact BVS?
-
BVS could be contacted at phone #919 474 6700 and can also be accessed through its website. BVS operates from 4721 Emperor Boulevard, Durham, NC 27703, US.
-
How many shares of BVS are traded daily?
-
The average number of BVS shares traded daily for last 3 months was 651.7K.
-
What is the market cap of BVS currently?
-
The market value of BVS currently stands at $783.17M with its latest stock price at $11.56